Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was valued “in the low- to mid-triple-digit millions Swiss francs.”
At between CHF 100 million and CHF 500 million, the transaction would amount to between $121.6 million to $608.2 million.
The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees.
The expansion would also add end-to-end development and manufacturing capabilities in the U.S., with the aim of supporting customers from clinical through commercial phases in growth areas that include antibody-drug conjugates (ADCs) and other bioconjugates, viral vectors for cell and gene therapies, as well…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
